

Gilbert Halley E  
Form 4  
April 03, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
*See* Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Gilbert Halley E

(Last) (First) (Middle)

C/O IRONWOOD  
PHARMACEUTICALS, INC., 301  
BINNEY STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
IRONWOOD  
PHARMACEUTICALS INC  
[IRWD]

3. Date of Earliest Transaction  
(Month/Day/Year)  
04/01/2019

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
☒ Officer (give title below) \_\_\_\_ Other (specify below)  
Chief Admin Officer & SVP

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	04/01/2019		A		17,165	A	11 242,295

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

Edgar Filing: Gilbert Halley E - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 9.12 <sup>(2)</sup> <sub>—</sub>	04/01/2019		A		1,506 <sub>(2)</sub>		<sup>(3)</sup> <sub>—</sub>	03/01/2026	Class A Common Stock	1,506
Employee Stock Option (Right to Buy)	\$ 14.93 <sub>(2)</sub>	04/01/2019		A		4,326 <sub>(2)</sub>		<sup>(4)</sup> <sub>—</sub>	02/27/2027	Class A Common Stock	4,326
Employee Stock Option (Right to Buy)	\$ 12.95 <sub>(2)</sub>	04/01/2019		A		5,949 <sub>(2)</sub>		<sup>(5)</sup> <sub>—</sub>	02/21/2028	Class A Common Stock	5,949
Employee Stock Option (Right to Buy)	\$ 11.49 <sub>(2)</sub>	04/01/2019		A		16,804 <sub>(2)</sub>		<sup>(6)</sup> <sub>—</sub>	01/29/2029	Class A Common Stock	16,804
Employee Stock Option (Right to Buy)	\$ 4.88 <sup>(2)</sup> <sub>—</sub>	04/01/2019		A		2,472 <sub>(2)</sub>		<sup>(7)</sup> <sub>—</sub>	07/28/2019	Class A Common Stock	2,472
Employee Stock Option (Right to Buy)	\$ 10.02 <sub>(8)</sub>							<sup>(9)</sup> <sub>—</sub>	02/02/2020	Class A Common Stock	60,000
Employee Stock Option (Right to	\$ 9.89 <sup>(8)</sup> <sub>—</sub>							<sup>(9)</sup> <sub>—</sub>	02/01/2021	Class A Common Stock	60,000

Buy)

Employee

Stock

Option

\$ 10.53

(Right to

Buy)

(9)

12/12/2021

Class A  
Common  
Stock

30,000

Employee

Stock

Option

\$ 13.11

(Right to

Buy)

(9)

02/01/2022

Class A  
Common  
Stock

45,000

Employee

Stock

Option

\$ 11.65

(Right to

Buy)

(9)

02/01/2023

Class A  
Common  
Stock

30,000

Employee

Stock

Option

\$ 10.25

(Right to

Buy)

(9)

12/02/2023

Class A  
Common  
Stock

25,000

Employee

Stock

Option

\$ 12.56

(Right to

Buy)

(9)

03/03/2024

Class A  
Common  
Stock

65,000

Employee

Stock

Option

\$ 13.91

(Right to

Buy)

(9)

03/16/2025

Class A  
Common  
Stock

57,500

## Reporting Owners

**Reporting Owner Name / Address****Relationships**

Director

10% Owner

Officer

Other

Gilbert Halley E  
C/O IRONWOOD PHARMACEUTICALS, INC.  
301 BINNEY STREET  
CAMBRIDGE, MA 02142

Chief Admin Officer &amp; SVP

## Signatures

/s/ Conor Kilroy,  
Attorney-in-Fact

04/03/2019

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) In connection with the separation (the "Separation") of Cycleron Therapeutics, Inc. ("Cycleron") from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 17,165 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation.

(2) Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted, and the reporting person received options to purchase shares of Cycleron Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award.

(3) The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2016.

(4) The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017.

(5) The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018.

(6) The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019.

(7) The option has vested as to 20,000 shares as of the date hereof. The remaining shares will vest upon the issuer's achievement of a certain milestone.

(8) Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cycleron Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award.

(9) This option, granted as an annual performance award, is presently exercisable in full.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.